EGFR and cancer: EGFR is overexpressed in many cancer types and contributes to therapy resistance mechanisms in cancer.5 Although first- and second-generation tyrosine kinase inhibitors (TKI) are routinely used in the clinic to treat EGFR overexpressing cancers, emergence of TKI resistance via EGFR mutations is a severe problem.